Kiniksa Pharmaceuticals International, plc
KNSA · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Feb 2026
Open the dashboardInfographicSummary
FY2025 key figures
| $ | FY2025 | FY2024 | Change |
|---|---|---|---|
| Revenue | $678M | $423M | +60.1% |
| Operating income | $77.2M | −$45.6M | |
| Net income | $59.0M | −$43.2M |
Latest quarter: Q3 2026
Form 10-Q · Three months ended Sep 30, 2026 · filed Oct 27, 2026
| $ | Q3 2026 | Year earlier | Change |
|---|---|---|---|
| Revenue | $286M | $181M | +58.1% |
| Operating income | $54.2M | $24.0M | +126% |
| Net income | $47.3M | $18.4M | +157% |
Q3 2026 dashboardQ3 2026 infographic
Questions
- What was Kiniksa's revenue in FY2025?
- $678M in FY2025 (Fiscal year ended Dec 31, 2025), +60.1% vs $423M a year earlier, per its 10-K filed Feb 2026.
- Was Kiniksa profitable in FY2025?
- Yes: net income was $59.0M and operating income $77.2M in FY2025.
- What was Kiniksa's revenue in Q3 2026?
- $286M (+58.1% vs a year earlier), per its Form 10-Q filed Oct 27, 2026.